ライフサイエンスコーパス: biglycan

1 an-1,2,4, glypican-1,2,3, versican, decorin, biglycan).

2 in (which is closely related in structure to biglycan).

3 own to bind to 2 host receptors, decorin and biglycan.

4 function for the decorin-family proteoglycan biglycan.

5 l-surface sites, such as the protein core of biglycan.

6 I, apoB, apoE, and the vascular proteoglycan biglycan.

7 inked oligosaccharides) forms of decorin and biglycan.

8 in disaccharides liberated from decorin and biglycan.

9 overlaps with the expression of decorin and biglycan.

10 % identical (and 70% similar) to decorin and biglycan.

11 the isolated binding factors as decorin and biglycan.

12 rich repeat chondroitin sulfate proteoglycan biglycan.

13 upon the chondroitin sulfate side chains of biglycan.

14 elated with increased expression of secreted biglycan.

15 LPL for versican and 20 microgram/ml LPL for biglycan.

16 te-oxidized LDL bound poorly to versican and biglycan.

17 cked by the structurally homologous protein, biglycan.

18 ology with peptide antibodies to decorin and biglycan.

19 st the proteoglycans aggrecan, versican, and biglycan.

20 can, and the small leucine-rich proteoglycan biglycan.

21 antially rescued by the addition of purified biglycan.

22 ructures of the core proteins of decorin and biglycan.

23 synthesis of versican, perlecan, and decorin/biglycan.

24 and also had reduced mRNA levels compared to biglycan.

25 assemble glycosaminoglycans onto recombinant biglycan.

26 in the production of approximately 10 mg of biglycan/10(9) cells per 24 h.

27 rain increased mRNA for versican (3.2-fold), biglycan (2.0-fold), and perlecan (2.0-fold), whereas de

28 ved in lipid signaling) and up-regulation of biglycan (a member of the small leucine-rich protein fam

29 lumican competes with CD14 to bind CpG DNA; biglycan, a lumican paralog, also binds CpG DNA and supp

30 Biglycan, a pericellular small leucine-rich proteoglycan

31 GF-beta, but protein expression and mRNA for biglycan, a proteoglycan present in fibrotic tissue, was

32 Biglycan, a proteoglycan that is structurally closely re

33 Biglycan, a related proteoglycan, had no effect.

34 ican-positive regions also immunostained for biglycan, a small leucine-rich dermatan sulfate proteogl

35 Biglycan, a small leucine-rich proteoglycan, is a nonfib

36 ed in the proteolysis of aggrecan as well as biglycan, a small leucine-rich proteoglycan.

37 predominantly synthesized by neurons, and of biglycan, a small, leucine-rich chondroitin sulfate prot

38 Several lines of evidence indicate that biglycan acts by recruiting utrophin protein to the musc

39 r analysis shows that, with the exception of biglycan, all known SLRP genes reside in three gene clus

40 oE-containing but not apoE-free HDL and that biglycan also binds LDL.

41 protein retention by regulating synthesis of biglycan and also by altering glycosaminoglycan synthesi

42 Thus, biglycan and decorin appear to be essential for maintain

43 Biglycan and decorin are small dermatan sulfate-containi

44 of (125)I-labeled decorin and -biglycan, and biglycan and decorin competed for the SR-A-mediated cell

45 e of newly synthesized and total accumulated biglycan and decorin decreased by approximately 25%.

46 ermine if blocking TFGbeta signaling changed biglycan and decorin distribution.

47 In conclusion, both biglycan and decorin from atherosclerotic plaque possess

48 Biglycan and decorin from plaque exhibited a 24-75% and

49 Biglycan and decorin have been overexpressed in eukaryot

50 Loss of the ability of biglycan and decorin in atherosclerotic lesions to regul

51 PG-2 and PG-3 were identified as biglycan and decorin in Western blot analyses using anti

52 to analyze the HCII-stimulatory activity of biglycan and decorin isolated from normal human aorta an

53 The temporal expression of biglycan and decorin on the apical surface of MEE, combi

54 Immunohistochemistry of both biglycan and decorin revealed expression on the apical a

55 ression of specific messenger RNA (mRNA) for biglycan and decorin was determined with quantitative re

56 The renal proteoglycans biglycan and decorin were detectable in glomeruli, with

57 bserved in the cell-associated matrix, while biglycan and decorin were secreted into the medium of mo

58 asporin gene structure is similar to that of biglycan and decorin with 8 exons.

59 For biglycan and decorin, iduronate content was linearly cor

60 ed position at the C-terminal domain of both biglycan and decorin, is found in similar microenvironme

61 actor-beta (TGF-beta)-binding proteoglycans, biglycan and decorin, prevents TGF-beta from proper sequ

62 Biglycan and decorin, proteoglycans of the extracellular

63 Interestingly, the levels of biglycan and decorin, small leucine-rich proteoglycans,

64 n this study, we identified 2 proteoglycans, biglycan and decorin, that were expressed in the palatal

65 ers of the small leucine-rich proteoglycans, biglycan and decorin, we uncovered a role for these two

66 third peak contained the small proteoglycans biglycan and decorin.

67 eficient in 2 extracellular matrix proteins, biglycan and fibromodulin (bgn(-/0)fmod(-/-)).

68 ritis that is deficient in two ECM proteins, biglycan and fibromodulin (Bgn(-/0)Fmod(-/-)).

69 Analysis of these data shows that biglycan and fibromodulin are critical for TMJ subchondr

70 condylar cartilage integrity and identified biglycan and fibromodulin as novel key players in regula

71 In vivo interactions of biglycan and fibromodulin, two SLRPs highly expressed in

72 ritical for chondrogenesis and binds to both biglycan and fibromodulin.

73 nd aggrecan ((374)ALGS) fragments as well as biglycan and link protein from the aortic wall.

74 activity reduced the LDL binding ability of biglycan and released LDL from human aortic lesions.

75 showed a significant relation between renal biglycan and renal apolipoprotein B content.

76 Renal biglycan and renal apolipoprotein B were colocalized, an

77 oE), and extracellular matrix proteoglycans (biglycan and versican) were identified on adjacent secti

78 ADAMTS-5 was accompanied by accumulation of biglycan and versican, the major lipoprotein-binding pro

79 DL, since it enables its binding to vascular biglycan and versican.

80 en fibrils in tendons from mice deficient in biglycan and/or fibromodulin are structurally and mechan

81 lly biomolecules that can induce osteogenic (biglycan) and fibrogenic (fibromodulin, decorin) phenoty

82 ns), proteoglycans (eg, versican, syndecans, biglycan), and glycosaminoglycans (eg, hyaluronan, hepar

83 analysis using specific antisera to decorin, biglycan, and aggrecan.

84 The spatial relationships of versican, biglycan, and apoE were compared on 68 human coronary ar

85 d for binding of (125)I-labeled decorin and -biglycan, and biglycan and decorin competed for the SR-A

86 unostaining results indicated that aggrecan, biglycan, and decorin are distributed throughout the thi

87 alpha, alone or in combination, on aggrecan, biglycan, and decorin core protein gene transcription an

88 The molecular sizes of versican, biglycan, and decorin increased in response to Ox-LDL, a

89 coding the cartilage proteoglycans aggrecan, biglycan, and decorin is differentially regulated by IFN

90 this recombinant protein to cleave aggrecan, biglycan, and decorin was investigated.

91 ontains three major proteoglycans; aggrecan, biglycan, and decorin.

92 GF-beta binding protein-1 (LTBP-1), decorin, biglycan, and fibromodulin can bind and potentially inhi

93 llular matrix remodeling such as hyaluronan, biglycan, and fibronectin.

94 Three genes (lumican, biglycan, and insulin-like growth factor binding protein

95 Immunolabeling for carboxymethyllysine, biglycan, and lipoprotein lipase was found in D-galactos

96 modeling genes include desmoplakin, SPARCL1, biglycan, and PECAM.

97 Strain also increased versican, biglycan, and perlecan core proteins, with a concomitant

98 ce and matrix proteoglycans (e.g., perlecan, biglycan, and syndecans 1 and 3) and mitogenesis-related

99 ng enzyme prolysyl oxidase, the proteoglycan biglycan, and the basement membrane protein laminin 5.

100 ed high levels of alpha-smooth muscle actin, biglycan, and the extra domain A (EDA or EIIIA) form of

101 gulated the expression of osteonectin/SPARC, biglycan, and type I collagen in calvaria.

102 c segments contained substantial deposits of biglycan, apoE, apoA-I, and apoB.

103 e binding of native LDL to both versican and biglycan, approaching saturation at 30-40 microgram/ml L

104 Decorin and biglycan are class I small leucine-rich proteoglycans (S

105 r these results demonstrate that decorin and biglycan are WISP-1 binding factors that can mediate and

106 es provide further evidence that decorin and biglycan assume different structures in solution.

107 d to interact in vitro with the proteoglycan biglycan (Bg), but the direct participation of apoE in t

108 Biglycan (Bgn) and Fibromodulin (Fmod) are subtypes of t

109 of an extracellular matrix, and we identify biglycan (Bgn) and fibromodulin (Fmod) as two critical c

110 The extracellular matrix protein biglycan (Bgn) is a leucine-rich proteoglycan that is in

111 Biglycan (bgn) is a small leucine-rich proteoglycan enri

112 While biglycan (BGN) is suggested to direct diverse signaling

113 Biglycan (Bgn), Tlr3, and IFN-alpha/beta receptor alpha

114 el were used to study the implication of the biglycan (BGN)-TLR3-IFN axis in both CAVD and bone forma

115 The biglycan binding site was mapped to the COOH-terminal th

116 Biglycan binding to alpha-dystroglycan was confirmed by

117 In vitro studies demonstrated that biglycan binds apoE-containing but not apoE-free HDL and

118 Biglycan binds MuSK and the levels of this receptor tyro

119 specifically stimulated mRNA expression for biglycan (but not versican or decorin), which was correl

120 Biglycan, but not decorin, from atherosclerotic plaque c

121 dies of structural and functional domains of biglycan by transient eukaryotic expression using the va

122 te proteoglycan, epiphycan, from decorin and biglycan by using dissociative extraction of bovine feta

123 was completely rescued by reintroduction of biglycan by viral transfection.

124 of elastin synthesis and assembly, and that biglycan can act as an important modulator of the compos

125 e cells were transduced with a GAG-deficient biglycan cDNA-containing retroviral vector (LmBSN).

126 Bone matrix markers (biglycan, COL1A1, tenascin C, and fibronectin) and low-d

127 6 (MT3-MMP) and decorin, and upregulation of biglycan, collagen V, collagen XII, PAI-1, Scleraxis, an

128 corneal regions, corroborating the idea that biglycan compensates for the loss of decorin.

129 genesis assays using recombinant decorin and biglycan confirmed a functional compensation, with both

130 oncentrations in plasma and increased aortic biglycan content compared with mice that received either

131 meruli, with a significant increase in renal biglycan content in diabetic mice on the high-cholestero

132 The increased renal biglycan content in diabetic nephropathy probably contri

133 The biglycan core protein also shows a similar steep transit

134 of recombinant chondroitin sulfate-modified biglycan core protein and restoration of fibroblast grow

135 nt vaccinia virus, vBGN4 encoding the mature biglycan core protein as a polyhistidine fusion protein

136 d core protein are very similar, whereas the biglycan core protein exhibits closer similarity to the

137 levels (-79%) and transcription rate of the biglycan core protein gene (-46%).

138 The inhibition of aggrecan, decorin, and biglycan core protein gene expression by the combination

139 ycan steady-state mRNA levels (-62%) and the biglycan core protein gene transcription rate (-18%).

140 lycan mRNA or the transcription rates of the biglycan core protein gene.

141 Both recombinant biglycan proteoglycan and biglycan core protein increased Wnt-induced beta-catenin

142 F-treated and wounded cultures increase both biglycan core protein synthesis and biglycan proteolytic

143 The mRNA and protein levels of biglycan, decorin, and fibromodulin increased synchronou

144 Beyond the fourth decade, decorin and biglycan decreased in all scleral regions and were prese

145 Biglycan-deficient cells treated with exogenous Wnt3a ha

146 ed protein 1 was decreased in bone formed by biglycan-deficient cells, further suggesting reduced Wnt

147 of several Wnt target genes were blunted in biglycan-deficient cells.

148 ssessed reduced activity with HCII, but only biglycan demonstrated a correlation between activity and

149 also were detected in regions with apoE and biglycan deposition.

150 a high degree of colocalization of apoE and biglycan deposits.

151 uble-deficiency of 2 SLRPs, fibromodulin and biglycan (dKO), acquire skeletal abnormalities, but thei

152 c evidence for an interaction of decorin and biglycan during corneal development and further suggest

153 sembly, a function that can be fine-tuned by biglycan during early development.

154 Biglycan (encoded by the gene Bgn) is an ECM proteoglyca

155 the small leucine-rich proteoglycan family, biglycan, enhances canonical Wnt signaling by mediating

156 Decorin and biglycan exhibited overlapping spatial expression patter

157 the B. burgdorferi s. l. complex, adhered to biglycan expressed by human endothelial cells in a flow-

158 tin sulfate chains, whereas about 50% of the biglycan expressed by UMR106 cells was substituted with

159 Finally, biglycan expression is elevated in muscle from the dystr

160 ely high levels in all developmental stages, biglycan expression was high early, decreased during dev

161 us bFGF is primarily responsible for altered biglycan expression, synthesis, and proteolytic processi

162 atory response of the host differ in a mouse biglycan expression- and Borrelia genospecies-dependent

163 Decorin and biglycan extracted from normal and diseased corneas exhi

164 ronan-binding large proteoglycans), decorin, biglycan, fibromodulin, and lumican (small proteoglycans

165 oteoglycan (SLRP) family, including decorin, biglycan, fibromodulin, and lumican.

166 s and bones, were investigated by generating biglycan/fibromodulin double-deficient mice.

167 ion of pathological tissue remodeling with a biglycan fragment (344)YWEVQPATFR, termed Bgm1, has been

168 ulation of a approximately 20-kDa N-terminal biglycan fragment in the culture media.

169 We found a compensatory up-regulation of biglycan gene expression in the decorin-deficient mice,

170 glutathione-S-transferase-fused recombinant biglycan (GST-BGN) on craniofacial bone regeneration.

171 although they are predominantly beta-sheet, biglycan has a significantly higher content of alpha-hel

172 tryptase, also degraded other alarmins, i.e. biglycan, HMGB1, and IL-33, a degradation that was effic

173 at a significant portion of the glypican and biglycan immunoreactivity colocalized with nuclear stain

174 ining was selective, insofar as glypican and biglycan immunoreactivity in the nucleus was seen predom

175 However, the role of biglycan in Borrelia infection has not been characterize

176 s showed an abnormal stromal localization of biglycan in pathologic corneas.

177 s, keratocan, lumican, mimecan, decorin, and biglycan in solution in vitro has been compared using re

178 el role for the extracellular matrix protein biglycan in synapse stability.

179 accumulation of decorin and particularly of biglycan in the affected corneas.

180 with hypotheses that predict involvement of biglycan in the control of cell migration.

181 e investigated the expression of decorin and biglycan in the cornea of mice deficient in either SLRP

182 lts also raise the possibility of a role for biglycan in the pathogenesis, and perhaps the treatment,

183 ighly charged molecular forms of decorin and biglycan, indicating modification of the proteins with d

184 Purified biglycan induces nNOS redistribution to the plasma membr

185 decorin, but not its homologous proteoglycan biglycan, inhibited LV sprouting in an ex vivo 3D model

186 Decorin and biglycan interacted directly with WISP-1 and inhibited i

187 Immunoprecipitation analysis revealed that biglycan interacts with both the canonical Wnt ligand Wn

188 phenotype in mesenchymal lineage cells with biglycan(+) intermediate fibroblasts as a major contribu

189 The proteoglycan biglycan is a receptor molecule for flow-resistant adhes

190 Biglycan is a small chondroitin sulfate proteoglycan fou

191 Biglycan is an ECM molecule that associates with the DAP

192 Together, these results indicate that biglycan is an extracellular ligand for MuSK that is imp

193 In muscle, biglycan is detected at both synaptic and nonsynaptic re

194 llopodia on migrating cells, indicating that biglycan is found at loci at which the formation and dis

195 We conclude that biglycan is important for the maintenance of muscle cell

196 The biological function of biglycan is poorly understood, although several studies

197 inantly in the macrophage-rich core, whereas biglycan is prominent in the smooth muscle cell matrix a

198 Biglycan is synthesized as a precursor with an NH(2)-ter

199 We infected biglycan knockout (KO) and wild-type (WT) C3H mice with

200 Instead, biglycan levels were increased, highlighting the role of

201 f ECM molecules in GBM and suggests that the biglycan-LRP6 axis could be a therapeutic target to curb

202 central nervous system regions, glypican and biglycan may be involved in the regulation of cell divis

203 These results suggest that biglycan may bind apoE and apoB in atherosclerotic intim

204 ings are consistent with the hypothesis that biglycan may contribute to the pathogenesis of atheroscl

205 We propose that biglycan may serve as a reservoir for Wnt in the pericel

206 We propose that biglycan modulates BMP-4-induced signaling to control os

207 ite, removing the propeptide and producing a biglycan molecule with an NH(2) terminus identical to th

208 on of the inhibitory effects of TNF alpha on biglycan mRNA levels (-79%) and transcription rate of th

209 used, IFN gamma did not alter the levels of biglycan mRNA or the transcription rates of the biglycan

210 Comparing biglycan mRNAs, (GU)25 replaced (CA)12.

211 tic development in fetal and early postnatal biglycan null (bgn(-/o)) muscle is indistinguishable fro

212 Here, we show that biglycan null mice exhibit a mild dystrophic phenotype a

213 1 and -2, and beta1- and beta2-syntrophin in biglycan null mice.

214 parable fibril structure in the decorin- and biglycan-null corneas compared with wild-type controls.

215 Notably, the corneas of compound decorin/biglycan-null mice showed severe disruption in fibril st

216 inhibited by dermatan sulfate, decorin, and biglycan or by treatment of the cell surface with dermat

217 Neointimae that formed from cells with biglycan or empty vector contained fewer and less aggreg

218 Control cells were transduced with either biglycan or empty vector.

219 Exogeneous biglycan or overexpression of biglycan resulted in a hig

220 ddition of LPL to oxidized LDL together with biglycan or versican allowed the oxidized LDL to bind th

221 reduction in collagen 3), but not periostin, biglycan, or fibronectin accumulation, was improved by a

222 Biglycan-overexpressing BTICs developed into larger tumo

223 Versican, biglycan, perlecan, and hyaluronan were present with var

224 o be identified and characterized along with biglycan (PG-I) and decorin (PG-II).

225 ginating from types I, II, and III collagen, biglycan, prolargin, fibromodulin, fibronectin, decorin,

226 Previous studies have shown that biglycan promotes hypoxic survival of disc progenitor ce

227 Biglycan protein and mRNA levels peaked as the palatal s

228 Biglycan protein injected into muscle becomes stably ass

229 Both recombinant biglycan proteoglycan and biglycan core protein increase

230 moval of the chondroitin sulfate chains from biglycan proteoglycan does not induce a shift to the cor

231 larity to the decorin glycoforms than to the biglycan proteoglycan form.

232 However, biglycan proteoglycan shows a broad unfolding transition

233 Far-UV CD spectroscopy of decorin and biglycan proteoglycans indicates that, although they are

234 ase both biglycan core protein synthesis and biglycan proteolytic processing, which results in the ac

235 ity and HCII stimulatory activity (r = 0.79, biglycan; r = 0.63, decorin; p < 0.05).

236 e show that the extracellular matrix protein biglycan regulates utrophin expression in immature muscl

237 and internalization) of (125)I-decorin and -biglycan, respectively.

238 This injected biglycan restores the sarcolemmal expression of alpha-dy

239 Exogeneous biglycan or overexpression of biglycan resulted in a higher proliferation rate of BTIC

240 n immature muscle and that recombinant human biglycan (rhBGN) increases utrophin expression in cultur

241 Biglycan RNA steady-state levels also selectively increa

242 Furthermore, biglycan's modulation of canonical Wnt signaling affecte

243 Biglycan-, sc1-, and SIM-Ig fusion proteins selectively

244 Approximately 70% of the recombinant biglycan secreted by HT-1080 cells was substituted with

245 The structure of the recombinant biglycan secreted by these cells was defined by analyzin

246 hese findings suggest that the GAG chains of biglycan serve as inhibitors of elastin synthesis and as

247 In contrast, TNF alpha decreased biglycan steady-state mRNA levels (-62%) and the biglyca

248 This approach resulted in the cloning of biglycan, syndecan 4, collagen type I, clusterin, matrix

249 expression of TGF-beta1 and matrix proteins (biglycan, tenascin, fibronectin, and type I collagen).

250 The decorin-null tissues contained more biglycan than control tissues, suggesting that this rela

251 ng the binding of native and oxidized LDL to biglycan than versican.

252 and activity for biosynthetic processing of biglycan, the latter with kinetics superior to those of

253 In contrast, less cleavage was observed for biglycan, the most closely related proteoglycan.

254 Exposure of decorin and biglycan to 10 M urea resulted in an increase in fluores

255 nally, immunocytochemical staining localizes biglycan to the tips and edges of lamellopodia on migrat

256 ic fibers as compared with empty vector- and biglycan-transduced cells.

257 ift assay, [(35)S]SO(4)-labeled versican and biglycan, two extracellular proteoglycans secreted by va

258 eavages in versican (V1 and V2 isoforms) and biglycan using a z-score approach based on label-free qu

259 Strong immunostaining for decorin, biglycan, versican, and hyaluronan is observed in both i

260 Furthermore, SAA up-regulated biglycan via the induction of endogenous transforming gr

261 Interestingly, recombinant biglycan was able to rescue impaired Wnt signaling cause

262 when the secondary structure of recombinant biglycan was disrupted by exposure to 4 M guanidine hydr

263 half of the pathologic corneas, the level of biglycan was elevated an average of seven times above no

264 The native recombinant biglycan was shown to bind to collagen type V and the co

265 eobox, Myoblast determination protein 1, and Biglycan were examined within clonal cell populations, c

266 acellular matrix proteoglycans keratocan and biglycan were quantified using ELISAs.

267 Glycoforms of biglycan were separated by imidazole gradient elution, u

268 I receptors; as well as LTBP-1, decorin, and biglycan were up-regulated during adult wound healing.

269 racellular matrix (ECM) molecules, including biglycan, were elevated in areas infiltrated with brain

270 roblasts (MEFs) produce only fully processed biglycan, whereas MEFs derived from embryos homozygous n

271 f the hyalectan gene family; and decorin and biglycan, which are members of a separate gene family, t

272 eoglycan that may influence elastogenesis is biglycan, which possesses two GAG chains.

273 inant PLTP markedly increased HDL binding to biglycan, which suggests that PLTP may mediate lipoprote

274 Exceptions to the localization of biglycan with apolipoproteins were found in regions that